<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01603355</url>
  </required_header>
  <id_info>
    <org_study_id>e8343</org_study_id>
    <nct_id>NCT01603355</nct_id>
  </id_info>
  <brief_title>Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis</brief_title>
  <official_title>An Open-label Trial to Assess the Efficacy and Safety of Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eric B. Suhler</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <brief_summary>
    <textblock>
      The investigators are doing this research study to see if tocilizumab (Actemra) is safe and&#xD;
      effective when used for severe or refractory non-infectious uveitis. Uveitis is an&#xD;
      inflammation of the eye that is caused by the body's immune system reacting against the eye&#xD;
      tissues.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    insufficient enrollment&#xD;
  </why_stopped>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Control of Ocular Inflammation</measure>
    <time_frame>16 Weeks</time_frame>
    <description>control of anterior chamber cell in both eyes at week 16 to a level of trace or less (SUN criteria) without an increase in any immunosuppressive treatment and while using prednisolone acetate topically no more than 2 times per day</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Juvenile Idiopathic Arthritis Associated Uveitis</condition>
  <arm_group>
    <arm_group_label>Tocilizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>Intravenous tocilizumab:&#xD;
Patients less than 30 kg weight:10 mg per kg every 4 weeks Patients at or above 30 kg weight: 8 mg per kg every 4 weeks</description>
    <arm_group_label>Tocilizumab</arm_group_label>
    <other_name>Actemra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with Juvenile Idiopathic Arthritis&#xD;
&#xD;
          -  Subjects with vision-threatening autoimmune uveitis.&#xD;
&#xD;
          -  Failure to respond to methotrexate or at least one other systemic immunosuppressive or&#xD;
             intolerance to such medications due to side effects. Failure to respond includes&#xD;
             presence of one plus or greater anterior chamber cell in both eyes; need for topical&#xD;
             corticosteroid four times or more in either eye; ocular hypertension or glaucoma&#xD;
             attributable to the topical corticosteroid.&#xD;
&#xD;
          -  Subjects with bilateral disease.&#xD;
&#xD;
          -  If subjects are on oral corticosteroids, the dosage must be stable for 2 weeks prior&#xD;
             to baseline and not exceed 10 mg per day or 2mg/kg/day (whichever is less) of&#xD;
             prednisone or its equivalent. Subjects must be willing to agree to not alter the&#xD;
             dosage of oral steroids during the first 16 weeks of the trial.&#xD;
&#xD;
          -  Must have a chest radiograph within 3 months prior to enrollment with no evidence of&#xD;
             malignancy, infection or fibrosis.&#xD;
&#xD;
          -  Parent or guardian must understand and voluntarily sign an informed consent form.&#xD;
&#xD;
          -  Pediatric subjects of either gender 2-17 years at time of consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability of parent or guardian to provide voluntary consent&#xD;
&#xD;
          -  Major surgery (including joint surgery) within 8 weeks prior to screening or planned&#xD;
             surgery within 12 months following randomization.&#xD;
&#xD;
          -  Any condition, including the presence of laboratory abnormalities, which places the&#xD;
             subject at unacceptable risk if he/she were to participate in the study or confounds&#xD;
             the ability to interpret data from the study&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Current liver disease, as determined by the Principal Investigator on the basis of&#xD;
             history or serum studies&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions to human, humanized or murine&#xD;
             monoclonal antibodies including tocilizumab.&#xD;
&#xD;
          -  Evidence of significant uncontrolled concomitant diseases such as nervous system,&#xD;
             renal, hepatic (patients with prior history of ALT elevation will not be excluded),&#xD;
             endocrine, or gastrointestinal (GI) disorders, which in the Investigator's opinion,&#xD;
             would preclude patient participation.&#xD;
&#xD;
          -  Uncontrolled disease states, such as asthma, psoriasis or inflammatory bowel disease&#xD;
             where flares are commonly treated with oral or parenteral corticosteroids.&#xD;
&#xD;
          -  Any major episode of infection requiring hospitalization or treatment with IV&#xD;
             antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to&#xD;
             screening&#xD;
&#xD;
          -  History of active mycobacterial infection with any species (including Mycobacterium&#xD;
             tuberculosis) within 2 years prior to screening visit. Subjects with Mycobacterium&#xD;
             tuberculosis infection more than 2 years prior to screening visit are allowed if&#xD;
             successful treatment was completed at least 2 years prior to randomization and is&#xD;
             documented and available for verification.&#xD;
&#xD;
          -  Immunization with a live/attenuated vaccine within 4 weeks prior to baseline&#xD;
&#xD;
          -  Latent Mycobacterium tuberculosis infection as indicated by a positive Purified&#xD;
             Protein Derivative [PPD] skin test. Subjects with a positive PPD skin test and&#xD;
             documented completion of treatment for latent TB are eligible. Subjects with a&#xD;
             positive PPD skin test and not treated or no documentation of completion of treatment&#xD;
             are ineligible.&#xD;
&#xD;
          -  If QuantiFERON® test is performed instead of the PPD test, only those with a negative&#xD;
             QuantiFERON® test are allowed in the study.&#xD;
&#xD;
          -  History of incompletely treated Mycobacterium tuberculosis infection as indicated by&#xD;
&#xD;
               -  Subject's medical records documenting incomplete treatment for Mycobacterium&#xD;
                  tuberculosis&#xD;
&#xD;
               -  Subject's self-reported history of incomplete treatment for Mycobacterium&#xD;
                  tuberculosis&#xD;
&#xD;
          -  History of recurrent bacterial infection (at least 3 major infections resulting in&#xD;
             hospitalization and/or requiring intravenous antibiotic treatment within the past 2&#xD;
             years) or recurrent viral, fungal, mycobacterial, or other infections (including but&#xD;
             not limited to atypical mycobacterial disease, hepatitis B and C, and herpes zoster,&#xD;
             but excluding fungal infections of the nail beds)&#xD;
&#xD;
          -  Clinically significant abnormality on the chest x-ray (CXR) at screening. Chest x-rays&#xD;
             performed within 3 months prior to start of study drug are acceptable.&#xD;
&#xD;
          -  Use of any investigational medication within 4 weeks prior to start of study drug or 5&#xD;
             pharmacokinetic/pharmacodynamic half-lives (whichever is longer)&#xD;
&#xD;
          -  History of congenital or acquired immunodeficiency (eg, Common Variable&#xD;
             Immunodeficiency [CVID])&#xD;
&#xD;
          -  Hepatitis B surface antigen positive or Hepatitis B core antibody positive at&#xD;
             screening&#xD;
&#xD;
          -  History of Human Immunodeficiency Virus (HIV) infection&#xD;
&#xD;
          -  Antibodies to Hepatitis C at screening&#xD;
&#xD;
          -  Malignancy or history of malignancy (except for treated [ie, cured] basal-cell skin&#xD;
             carcinomas &gt; 3 years prior to screening)&#xD;
&#xD;
          -  Have multiple sclerosis or other central demyelinating disorder.&#xD;
&#xD;
          -  Presence of a transplanted organ (with the exception of a corneal transplant performed&#xD;
             &gt; 3 months prior to enrollment).&#xD;
&#xD;
          -  History of substance abuse (drug or alcohol) within the previous 3 years, history of&#xD;
             noncompliance to medical regimens, or other condition/circumstance that could&#xD;
             interfere with the subject's adherence to protocol requirements.&#xD;
&#xD;
          -  Previous or current use of an alkylating agent (e.g. chlorambucil or&#xD;
             cyclophosphamide).&#xD;
&#xD;
          -  Treatment with etoposide (VP16) within 3 months prior to the baseline visit.&#xD;
&#xD;
          -  Administration of intravenous immunoglobulin for the treatment of active polyarticular&#xD;
             disease within 4 weeks prior to the baseline visit.&#xD;
&#xD;
          -  Previous treatment with any cell depleting therapies, including investigational agents&#xD;
             (e.g. anti-CD19 and anti-CD20).&#xD;
&#xD;
          -  Prior stem cell transplant at any time.&#xD;
&#xD;
          -  TNF -blocker use within the 8-weeks prior to enrollment (Infliximab use within 10&#xD;
             weeks prior to enrollment).&#xD;
&#xD;
          -  Laboratory Exclusion criteria (at screening):&#xD;
&#xD;
               -  Serum creatinine &gt;1.5 ULN (upper limit of normal for age and sex);&#xD;
&#xD;
               -  AST or ALT &gt; 1.5 ULN (upper limit of normal for age and sex);&#xD;
&#xD;
               -  Total bilirubin &gt; 1.3 mg/dL (&gt; 23 umol/L);&#xD;
&#xD;
               -  Platelet count &lt; 150 x 103/μL (&lt; 150,000/mm3);&#xD;
&#xD;
               -  Hemoglobin &lt; 9.0 g/dL (&lt; 3.7 mmol/L);&#xD;
&#xD;
               -  WBC count &lt; 5,000/mm3 (&lt; 5.0 x 109/L);&#xD;
&#xD;
               -  Neutrophil count &lt; 2,500/ mm3 (&lt; 2.5 x 109/L)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric B Suhler, MD,MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James T Rosenbaum, MD</last_name>
    <role>Study Director</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 18, 2012</study_first_submitted>
  <study_first_submitted_qc>May 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2012</study_first_posted>
  <results_first_submitted>October 27, 2018</results_first_submitted>
  <results_first_submitted_qc>October 27, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 27, 2018</results_first_posted>
  <last_update_submitted>January 2, 2019</last_update_submitted>
  <last_update_submitted_qc>January 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Eric B. Suhler</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>JIA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
    <mesh_term>Uveitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tocilizumab</title>
          <description>Tocilizumab: Intravenous tocilizumab:&#xD;
Patients less than 30 kg weight:10 mg per kg every 4 weeks Patients at or above 30 kg weight: 8 mg per kg every 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tocilizumab</title>
          <description>Tocilizumab: Intravenous tocilizumab:&#xD;
Patients less than 30 kg weight:10 mg per kg every 4 weeks Patients at or above 30 kg weight: 8 mg per kg every 4 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants with control of ocular inflammation at trace or less</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Control of Ocular Inflammation</title>
        <description>control of anterior chamber cell in both eyes at week 16 to a level of trace or less (SUN criteria) without an increase in any immunosuppressive treatment and while using prednisolone acetate topically no more than 2 times per day</description>
        <time_frame>16 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab</title>
            <description>Tocilizumab: Intravenous tocilizumab:&#xD;
Patients less than 30 kg weight:10 mg per kg every 4 weeks Patients at or above 30 kg weight: 8 mg per kg every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Control of Ocular Inflammation</title>
          <description>control of anterior chamber cell in both eyes at week 16 to a level of trace or less (SUN criteria) without an increase in any immunosuppressive treatment and while using prednisolone acetate topically no more than 2 times per day</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tocilizumab</title>
          <description>Tocilizumab: Intravenous tocilizumab:&#xD;
Patients less than 30 kg weight:10 mg per kg every 4 weeks Patients at or above 30 kg weight: 8 mg per kg every 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Eric Suhler</name_or_title>
      <organization>Oregon Health &amp; Science University</organization>
      <phone>503-494-5023</phone>
      <email>suhlere@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

